Community Screening and Management of Hepatitis B, C and Delta in the Mongolian Population Living in France
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Community screening for hepatitis B, C and delta in the Mongolian population living in France.
- Who it may be relevant to
- Registry conditions: HEPATITIS C (HCV), Hepatitis B Virus (HBV), Hepatitis D, Hepatocellular Carcinoma (HCC). Basic parameters: from 15 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- France
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Community Screening for Hepatitis B, C and Delta in the Mongolian Population Living in France
Overview
In Mongolia, mortality from hepatocellular carcinoma (HCC) is one of the highest in the world. Viral hepatitis is the main cause of HCC: the prevalence of hepatitis B (HBV) estimated at 11% In Mongolia, hepatitis C (HCV) at 8.5%, and hepatitis Delta (HDV) at 40-60% in HBV-infected patients. Viral hepatitis are essentially asymptomatic and therefore require systematic screening for diagnosis. Once a diagnosis of chronic viral infection has been established, specific therapies are available to reduce the morbidity and mortality of these patients. A study carried out in California in the Mongolian community found an HBV prevalence of 9.7% and positive HDV serology in 41% of these patients. There is a large Mongolian community in France, estimated at between 5,000 and 6,000 patients. Although the majority of these patients are covered by French social security; however, access to care and screening for viral hepatitis often remain difficult and insufficient for migrant or vulnerable populations in France The aim of this study is to screen the Mongolian community in France for viral hepatitis, and then initiate a program of care and treatment.
Interventions
- Diagnostic test Community screening for hepatitis B, C and delta in the Mongolian population living in France
Screening will be organised in 11 centres in France, with 1 to 3 screening sessions per centre: patients will be informed of these screening sessions by the Mongolian Embassy in France, social networks and communities. During this screening visit, Rapid Diagnostic Orientation Test (RDOT) will be carried out to screen for HBV and HCV. If the RDOT is negative for both viruses, an information on transmission and prevention of viral infection will be given. If the RDOT is positive, confirmation of
Primary outcome measures
- Number of patients positive for hepatitis B, hepatitis C and hepatitis D. [Time frame: Visit 2 (Day 0 to Mounth 4)]
Secondary outcome measures (6)
- Cascade of care for this screening strategy [Time frame: 12 months after positive TROD screening]
- Information on preventing viral hepatitis [Time frame: Baseline]
- Characterisation of liver fibrosis in patients with chronic viral hepatitis [Time frame: Day 1 or up to 4 months]
- Characterisation of liver fibrosis in patients with chronic viral hepatitis [Time frame: Liver fibrosis will be assessed by elastometry and a FibroTest blood test, carried out according to the procedures of each centre, either during screening or at the specialist consultation.]
- Risk of hepatocellular carcinoma in patients positive for viral hepatitis [Time frame: Day 1 or up to 4 months]
- Risk of hepatocellular carcinoma in patients positive for viral hepatitis [Time frame: Day 1 or up to 4 months]
Eligibility criteria
Inclusion criteria
- Mongolian people
- Over 15 years of age
- Living in France
- Majors agree to participate or minors whose parental guardians agree to their child's participation in the study
Exclusion criteria
- People already followed for viral hepatitis, treated or not treated
- Persons deprived of their liberty by a judicial or administrative decision
- Adults subject to a legal protection measure (guardianship, curators)
- People participate in any interventional research except routine care research (old regulation) and category 2 research that does not interfere with the primary endpoint analysis
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
France · 11 centers
- Centre Hospitalier Annecy Genevois — Annecy
- Centre Expert Hépatites Virales Aquitaine, CHU de Bordeaux — Bordeaux
- CHU de Clermont Ferrand — Clermont-Ferrand
- Hôpital Henri Mondor - Assistante Publique Hopitaux de Paris (APHP) — Créteil
- CHU Grenoble Alpes — Grenoble
- CHRU Lille — Lille
- Service d'Hépatologie, Institut d'hépatologie de Lyon, Hôpital Croix-Rousse, Hospices Civi — Lyon
- CHRU Rennes Pontchaillou — Rennes
- … and 3 more centers
Identifiers
NCT: NCT07038863 · 69HCL24_0469 · 2025-A00086-43